Compare Stocks

Date Range: 

 Enanta PharmaceuticalsPhibro Animal HealthG1 TherapeuticsAkero TherapeuticsTrillium Therapeutics
SymbolNASDAQ:ENTANASDAQ:PAHCNASDAQ:GTHXNASDAQ:AKRONASDAQ:TRIL
Price Information
Current Price$48.50$27.45$20.60$27.33$9.59
52 Week RangeHoldHoldBuyBuyBuy
MarketRank™
Overall Score1.41.71.51.71.7
Analysis Score3.10.83.54.53.5
Community Score2.32.22.42.42.9
Dividend Score0.02.50.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.01.30.00.00.6
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyBuy
Consensus Price Target$65.29$21.50$49.17$57.29$21.83
% Upside from Price Target34.61% upside-21.68% downside138.67% upside109.61% upside127.67% upside
Trade Information
Market Cap$978.34 million$1.11 billion$866.40 million$951.63 million$988.09 million
Beta0.540.462.440.582.27
Average Volume142,019138,0961,405,299282,9311,441,325
Sales & Book Value
Annual Revenue$122.47 million$800.40 millionN/AN/A$120,000.00
Price / Sales7.991.39N/AN/A8,234.05
CashflowN/A$2.47 per shareN/AN/AN/A
Price / CashN/A11.10N/AN/AN/A
Book Value$22.70 per share$4.65 per share$6.80 per share$4.51 per share($0.86) per share
Price / Book2.145.90N/AN/A-11.15
Profitability
Net Income$-36,170,000.00$33.55 million$-122,450,000.00$-43,760,000.00$-41,620,000.00
EPS($0.89)$1.08($3.27)($2.90)($1.38)
Trailing P/E RatioN/A25.90N/AN/AN/A
Forward P/E RatioN/A24.29N/AN/AN/A
P/E GrowthN/A2.00N/AN/AN/A
Net Margins-29.53%5.37%N/AN/AN/A
Return on Equity (ROE)-3.75%23.70%-49.35%-40.84%-70.00%
Return on Assets (ROA)-3.53%5.99%-41.53%-38.33%-28.84%
Dividend
Annual PayoutN/A$0.48N/AN/AN/A
Dividend YieldN/A1.75%N/AN/AN/A
Three-Year Dividend GrowthN/A20.00%N/AN/AN/A
Payout RatioN/A44.44%N/AN/AN/A
Years of Consecutive Dividend GrowthN/A1 YearsN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.97%0.10%N/AN/A
Current Ratio18.08%2.88%7.45%24.81%22.44%
Quick Ratio18.08%1.61%7.45%24.81%22.44%
Ownership Information
Institutional Ownership Percentage90.78%50.32%77.89%83.49%67.46%
Insider Ownership Percentage10.93%50.05%14.49%7.09%N/A
Miscellaneous
Employees1411,70012221N/A
Shares Outstanding20.17 million40.45 million42.06 million34.82 million103.03 million
Next Earnings Date8/3/2021 (Estimated)8/25/2021 (Estimated)8/4/2021 (Estimated)5/12/2021 (Estimated)5/21/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Trillium: Q1 Earnings SnapshotTrillium: Q1 Earnings Snapshot
sfgate.com - May 7 at 8:27 AM
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial ResultsTrillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
finance.yahoo.com - May 7 at 8:27 AM
Trillium Therapeutics (NASDAQ:TRIL) Shares Up 8.3%Trillium Therapeutics (NASDAQ:TRIL) Shares Up 8.3%
americanbankingnews.com - May 5 at 1:15 PM
CANADA STOCKS - TSX falls 0.77% to 19,108.33CANADA STOCKS - TSX falls 0.77% to 19,108.33
nasdaq.com - April 30 at 5:54 PM
Trillium Therapeutics (NASDAQ:TRIL) Upgraded to Buy at Bloom BurtonTrillium Therapeutics (NASDAQ:TRIL) Upgraded to Buy at Bloom Burton
americanbankingnews.com - April 30 at 7:09 AM
Trillium Therapeutics (NASDAQ:TRIL) Upgraded by Bloom Burton to "Buy"Trillium Therapeutics (NASDAQ:TRIL) Upgraded by Bloom Burton to "Buy"
marketbeat.com - April 30 at 6:22 AM
Trillium Therapeutics (NASDAQ:TRIL) Stock Price Up 5%Trillium Therapeutics (NASDAQ:TRIL) Stock Price Up 5%
americanbankingnews.com - April 29 at 3:56 PM
Trillium Therapeutics (TSX:TRIL): A Pharma Stock With Huge Upside PotentialTrillium Therapeutics (TSX:TRIL): A Pharma Stock With Huge Upside Potential
ca.finance.yahoo.com - April 29 at 3:44 PM
TSX Trumpets Triple-Digit GainsTSX Trumpets Triple-Digit Gains
baystreet.ca - April 28 at 12:40 PM
Trillium Therapeutics (NASDAQ:TRIL)  Shares Down 8.1% Trillium Therapeutics (NASDAQ:TRIL) Shares Down 8.1%
americanbankingnews.com - April 28 at 12:38 PM
TRIL May 2021 17.500 putTRIL May 2021 17.500 put
uk.finance.yahoo.com - April 28 at 7:35 AM
Trillium moves ‘don’t eat me’ cancer drug into new studies, but future clouded by modest tumor responsesTrillium moves ‘don’t eat me’ cancer drug into new studies, but future clouded by modest tumor responses
statnews.com - April 28 at 7:35 AM
Trillium unveils CD47 clinical research priorities as investors await solid tumor dataTrillium unveils CD47 clinical research priorities as investors await solid tumor data
fiercebiotech.com - April 28 at 7:35 AM
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance ChangesTrillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes
finance.yahoo.com - April 28 at 7:35 AM
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple MyelomaTrillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
finance.yahoo.com - April 28 at 7:35 AM
Trillium Therapeutics Inc. (NASDAQ:TRIL): A Business Review And Growth ForecastTrillium Therapeutics Inc. (NASDAQ:TRIL): A Business Review And Growth Forecast
marketingsentinel.com - April 27 at 12:57 PM
Trillium Therapeutics (NASDAQ:TRIL) Sees Unusually-High Trading VolumeTrillium Therapeutics (NASDAQ:TRIL) Sees Unusually-High Trading Volume
americanbankingnews.com - April 27 at 12:52 PM
Trillium Therapeutics (NASDAQ:TRIL) Rating Reiterated by JonestradingTrillium Therapeutics (NASDAQ:TRIL) Rating Reiterated by Jonestrading
americanbankingnews.com - April 26 at 1:12 PM
 Brokerages Expect Trillium Therapeutics Inc. (NASDAQ:TRIL) Will Announce Earnings of -$0.18 Per Share Brokerages Expect Trillium Therapeutics Inc. (NASDAQ:TRIL) Will Announce Earnings of -$0.18 Per Share
americanbankingnews.com - April 23 at 8:30 AM
Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 3.5%Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 3.5%
americanbankingnews.com - April 22 at 12:50 PM
Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 3.5%Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 3.5%
americanbankingnews.com - April 22 at 12:50 PM
Trillium Therapeutics (NASDAQ:TRIL) Now Covered by BenchmarkTrillium Therapeutics (NASDAQ:TRIL) Now Covered by Benchmark
americanbankingnews.com - April 20 at 9:02 AM
Contrasting Trillium Therapeutics (NASDAQ:TRIL) & Shiseido (OTCMKTS:SSDOY)Contrasting Trillium Therapeutics (NASDAQ:TRIL) & Shiseido (OTCMKTS:SSDOY)
americanbankingnews.com - April 18 at 2:16 AM
Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 5.1%Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 5.1%
americanbankingnews.com - April 17 at 9:08 AM
Benchmark Initiates Coverage on Trillium Therapeutics (NASDAQ:TRIL)Benchmark Initiates Coverage on Trillium Therapeutics (NASDAQ:TRIL)
americanbankingnews.com - April 14 at 9:18 AM
These 3 Stocks Will Make You A Fortune If They SucceedThese 3 Stocks Will Make You A Fortune If They Succeed
finance.yahoo.com - April 1 at 8:55 AM
DateCompanyBrokerageAction
2/9/2021Enanta PharmaceuticalsRoyal Bank of CanadaBoost Price Target
1/29/2021Enanta PharmaceuticalsJPMorgan Chase & Co.Upgrade
11/23/2020Enanta PharmaceuticalsEvercore ISIInitiated Coverage
10/26/2020Enanta PharmaceuticalsRoth CapitalBoost Price Target
9/23/2020Enanta PharmaceuticalsOppenheimerReiterated Rating
8/25/2020Enanta PharmaceuticalsPiper SandlerInitiated Coverage
7/27/2020Enanta PharmaceuticalsJMP SecuritiesUpgrade
3/17/2020Enanta PharmaceuticalsRobert W. BairdUpgrade
9/18/2019Enanta PharmaceuticalsBerenberg BankSet Price Target
5/24/2019Enanta PharmaceuticalsWolfe ResearchInitiated Coverage
8/8/2018Enanta PharmaceuticalsUBS GroupDowngrade
8/6/2020Phibro Animal HealthMorgan StanleyDowngrade
5/8/2020Phibro Animal HealthCredit Suisse GroupLower Price Target
3/31/2020Phibro Animal HealthG.ResearchUpgrade
2/6/2020Phibro Animal HealthGabelliDowngrade
1/28/2020Phibro Animal HealthBarclaysUpgrade
8/29/2019Phibro Animal HealthBank of AmericaLower Price Target
5/23/2019Phibro Animal HealthGuggenheimInitiated Coverage
4/9/2021G1 TherapeuticsNeedham & Company LLCReiterated Rating
11/17/2020G1 TherapeuticsRaymond JamesDowngrade
10/5/2020G1 TherapeuticsHC WainwrightReiterated Rating
8/20/2020G1 TherapeuticsWedbushReiterated Rating
8/9/2020G1 TherapeuticsCowenReiterated Rating
1/7/2020G1 TherapeuticsBTIG ResearchBoost Price Target
3/24/2021Akero TherapeuticsCanaccord GenuityLower Price Target
3/23/2021Akero TherapeuticsJefferies Financial GroupReiterated Rating
3/23/2021Akero TherapeuticsChardan CapitalBoost Price Target
4/29/2021Trillium TherapeuticsBloom BurtonUpgrade
4/26/2021Trillium TherapeuticsJonestradingReiterated Rating
4/20/2021Trillium TherapeuticsBenchmarkInitiated Coverage
11/18/2020Trillium TherapeuticsCraig HallumBoost Price Target
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.